Loading..
  • Vivesto logo
  • Vivesto logo
Vivesto
  • About Us
  • Technology & Pipeline
  • Governance
  • Investors
  • Media
  • Contact
  • About Us
    • CEO corner
    • Organisation
      • Management
      • Board of Directors
    • Partnering
    • Career
      • Vacant positions
    • Sustainability / Corporate Responsibility
  • Technology & Pipeline
    • XR Technology Platform
      • Benefits
      • Therapeutic focus
      • IP protection
    • Commercialized products
      • Apealea
    • Project Pipeline
      • Cantrixil
      • Docetaxel Micellar
    • Animal Health
  • Corporate Governance
    • Governance reports
    • General Meeting
    • Management
    • Board of Directors
    • Nomination Committee
    • Remuneration
    • Auditor
    • Code of Conduct
    • Articles of Association
    • Documents
  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
  • Media
    • Press releases
    • Events
    • Subscribe
    • Image Bank
    • Contact
  • Contact

Financial Reports and Presentations

2013
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2012
  • 2011
  • 2010
  • 2009
  • 2008
  • 2007
  • 2006
  • 2005
  • 1970
  • All years
Type of information
  • Interim reports
  • Annual reports
  • Presentations
  • Other
 Report
December 5, 2013Interim Report May – October 2013
September 6, 2013Interim Report May – July 2013
March 1, 2013Interim Report May 2012 – January 2013

Share this page

Investor contact
[email protected]
+46 18-50 54 40

Subscribe to our news

  • Investors
    • The Share
    • Ownership Structure
    • Financial Reports and Presentations
    • Analyst coverage
    • Prospectuses
    • Archive US listing
      • SEC Filings
      • Info regarding delisting of ADS from NASDAQ US
    • Press releases
    • Financial calendar
    • Subscribe
    • Contact
Vivesto logo
  • About Us
  • Technology & Pipeline
  • Corporate Governance
  • Investors
  • Media
  • Contact

Vivesto is a Swedish development company that aims to offer new treatment options for hard-to-treat cancers where there are major medical needs and significant market potential. The project portfolio consists of Cantrixil and Docetaxel micellar, which are being developed for blood cancer and prostate cancer, respectively, and the veterinary oncology program Paccal Vet (paclitaxel micellar), which is being evaluated in a pilot clinical trial in dogs with splenic hemangiosarcoma.

The Share

Follow the share
  • Personal data
  • Cookies

OAS-MA-P-001-SEP2020

Box 3061
169 03 Solna, Sweden
Tel +46 18 50 54 40
Fax +46 18 51 08 73
info@vivesto.com